DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
1404
BARECETAMAB
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Unknown
BARECETAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
M9SE4M9U1V
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SONTUZUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Mucin-1 other
SONTUZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
3VD89OE565
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OTLERTUZUMAB
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell
Leukocyte antigen CD37 binding agent
OTLERTUZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
2MZ3L2664T
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BUDIGALIMAB
1
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; HIV Infections; Melanoma; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung
Programmed cell death protein 1 inhibitor
BUDIGALIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
6VDO4TY3OO
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PINATUZUMAB VEDOTIN
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse
CD22 binding agent
PINATUZUMAB VEDOTIN
×
Maximum Phase:
1
First Approval:
None
UNII:
6KA1906BLC
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CM-101
1
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
CM-101
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TNX-100
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
TNX-100
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AFASEVIKUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Interleukin 17A inhibitor
AFASEVIKUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
TG8A3DSU6Z
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BIVATUZUMAB MERTANSINE
1
Antibody
Investigational
Unknown
Unknown
Unknown
CD44 antigen binding agent
BIVATUZUMAB MERTANSINE
×
Maximum Phase:
1
First Approval:
None
UNII:
074GT4PR9D
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ONGERICIMAB
1
Antibody
Investigational
Unknown
Unknown
Hypercholesterolemia; Neoplasms; Hyperlipidemia, Familial Combined; Hyperlipidemias; Hyperlipoproteinemia Type II
Subtilisin/kexin type 9 inhibitor
ONGERICIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
X126G5DZ36
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PIMURUTAMAB
1
Antibody
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Nasopharyngeal Neoplasms; Small Cell Lung Carcinoma
Epidermal growth factor receptor erbB1 inhibitor
PIMURUTAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
5V1Y8T4RB6
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LBY-135
1
Antibody
Investigational
Unknown
Unknown
Unknown
Tumor necrosis factor receptor superfamily member 10B agonist
LBY-135
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
KB-004
1
Antibody
Investigational
Unknown
Unknown
Glioblastoma; Myelodysplastic Syndromes; Primary Myelofibrosis
Ephrin type-A receptor 3 inhibitor
KB-004
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LINTUZUMAB ACTINIUM AC-225
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
LINTUZUMAB ACTINIUM AC-225
×
Maximum Phase:
1
First Approval:
None
UNII:
V860J30J9N
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EMERFETAMAB
1
Antibody
Unknown
Unknown
Unknown
Leukemia, Myeloid, Acute
Unknown
EMERFETAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
HOG226RYH1
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VANTICTUMAB
1
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Neoplasms; Pancreatic Neoplasms
Frizzled-1 antagonist
VANTICTUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
88WBI2D80S
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CHS-114
1
Antibody
Unknown
Unknown
Unknown
Carcinoma, Squamous Cell
Unknown
CHS-114
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LMB-7
1
Antibody
Investigational
Unknown
Unknown
Central Nervous System Neoplasms
Elongation factor 2 inhibitor
LMB-7
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FP-1305
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
FP-1305
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ENAVATUZUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Tumor necrosis factor receptor superfamily member 12A agonist
ENAVATUZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
914910XFBB
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NAVICIXIZUMAB
1
Antibody
Investigational
Unknown
Unknown
Fallopian Tube Neoplasms; Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms
Unknown
NAVICIXIZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
1W14T9L25W
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LEMZOPARLIMAB
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Neoplasms; Myelodysplastic Syndromes
Unknown
LEMZOPARLIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
0H2XLR2IKW
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AVIZAKIMAB
1
Antibody
Investigational
Unknown
Unknown
Lupus Erythematosus, Systemic
Unknown
AVIZAKIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
4H3BBE5WVK
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AVE-9633
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Myeloid
Myeloid cell surface antigen CD33 binding agent
AVE-9633
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ORILANOLIMAB
1
Antibody
Investigational
Unknown
Unknown
Autoimmune Diseases; Immunoglobulin G4-Related Disease; Pemphigus; Anemia, Hemolytic, Autoimmune; Myasthenia Gravis
IgG receptor FcRn large subunit p51 antagonist
ORILANOLIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
1LTT6HMX9N
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PERAKIZUMAB
1
Antibody
Investigational
Unknown
Unknown
Arthritis, Psoriatic
Interleukin 17A inhibitor
PERAKIZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
867X5909JO
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZIRALIMUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Basigin inhibitor
ZIRALIMUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
M87C8Y2GMN
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LUMILIXIMAB
1
Antibody
Investigational
Unknown
Unknown
Leukemia; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell
Immunoglobulin epsilon Fc receptor antagonist
LUMILIXIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
8Z13S29R5A
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
INDIUM IN 111 ALTUMOMAB PENTETATE
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
INDIUM IN 111 ALTUMOMAB PENTETATE
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SC-1
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
SC-1
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MFGR1877S
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MFGR1877S
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IDEC-159 111IN
1
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms
Tumor-associated antigen 72 binding agent
IDEC-159 111IN
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NELMASTOBART
1
Antibody
Unknown
Unknown
Unknown
Neoplasms
Unknown
NELMASTOBART
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ACAPATAMAB
1
Antibody
Unknown
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant
Unknown
ACAPATAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
GW5EID3IDO
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PG-110
1
Antibody
Investigational
Unknown
Unknown
Osteoarthritis, Knee
Beta-nerve growth factor inhibitor
PG-110
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
10
11
12
13
14
15
16
…
40
41
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA